Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591209 | 0.81 | — | — | |
| SCHEMBL17712573 | 0.77 | MAPT (0.35) | MEN1USP2ALDH1A1MAPTHPGD | |
| SCHEMBL1253872 | 0.76 | — | — | |
| SCHEMBL29048425 | 0.75 | — | — | |
| SCHEMBL658838 | 0.74 | PRMT6 (0.31) | MAPT | |
| SCHEMBL1992492 | 0.74 | — | — | |
| SCHEMBL30460336 | 0.73 | — | — | |
| SCHEMBL15721102 | 0.73 | MEN1 (0.32) | MEN1USP2ALDH1A1MAPTHPGD | |
| SCHEMBL29981380 | 0.73 | — | — | |
| SCHEMBL3327495 | 0.73 | JAK2 (0.30) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20110124672-A1 | Thienyl Compounds | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-1499615-B1 | THIENYL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20070142419-A1 | Thienyl Compounds | CHANG HUI-FANG | 2007-06-21 | — | — | US | disclosed |
| US-7186836-B2 | Thienyl compounds | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-20050171106-A1 | Thienyl compounds | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| EP-1499615-A1 | THIENYL COMPOUNDS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003087103-A1 | THIENYL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124672-A1 | Thienyl Compounds | AR, TPMT, TBXA2R | MEN1 1306/4885USP2 4817/4885ALDH1A1 138/4885 |
| US-20050171106-A1 | Thienyl compounds | AR, TBXA2R, TPMT | MEN1 1439/4885USP2 4800/4885ALDH1A1 143/4885 |
| US-20070142419-A1 | Thienyl Compounds | AR, TPMT, TBXA2R | MEN1 1306/4885USP2 4817/4885ALDH1A1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.